Plain-English translation of NCT06960863 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand whether a simple, painless ultrasound scan called Fibroscan can predict how well immunotherapy will work for people with advanced liver cancer. The study will compare your scan results and blood tests before and after 6 months of immunotherapy to see if the scan can show who is responding well to the medication and help doctors catch any liver problems early.
Currently, doctors struggle to know early on whether immunotherapy will help individual liver cancer patients, and they want better tools to spot liver damage before it becomes serious. This study tests whether Fibroscan—a non-invasive, quick ultrasound—can fill that gap and guide treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic at the start for blood tests, physical exam, imaging scans (ultrasound and CT or MRI), and a Fibroscan ultrasound to measure your liver stiffness. Then you will receive your immunotherapy treatment for 6 months. At 6 months, you will return for follow-up visits with blood tests, imaging scans, another Fibroscan, and an evaluation of any side effects—allowing researchers to see whether the Fibroscan predicted your response to treatment.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Egypt